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Mechanisms of melanoma cell adhesion to fibronectin.
ERIK HJ DANEN, DIRK J RUITER, and GOOS NP VAN MUUEN. 
Dept, o f Pathology, University Hospital, Nijmegen, The Netherlands.
Recent observations have shown that besides soluble factors, also 
the extracellular matrix influences gene expression and controls 
proliferation and differentiation of cells. The integrin family o f cell 
surface receptors is involved in the transduction o f signals from the 
extracellular matrix to the nucleus [1]. This function, together with 
their role in cell adhesion and migration has initiated much research 
on the role o f integrins in cancer. For human melanoma, changes in 
the expression o f «3/31, a4/Sl, a5/51, and av/33 have been found to 
correlate with tumor progression [reviewed in 2]. All these integrins 
can bind fibronectin (Fn).
We have investigated the mechanism of adhesion to Fn o f  human 
melanocytes (met) and four human melanoma cell lines with different 
metastatic capacities in nude mice. All 4 melanoma cell lines 
investigated were tumorigenic but IF6 and 530 were non-metastatic 
whereas BLM and MV3 were highly metastatic (fig. 1). In line with 
these findings, only BLM and MV3 were highly invasive through a
the central cell
binding domain.
The fact that only 
met, IF6, and 530 
adhered to the 
GRGDSP peptide, 
was likely to be due 
to lack of av|83 on 
BLM and MV3.
We performed 
antibody inhibition 
studies to identify 
integrins involved 
in adhesion to the 
different adhesive 
ligands. Adhesion 
of all melanoma 
cell lines to CS-I was blocked by mAbs to a4/Sl (fig. 5). P1B5 anti­
c s  had no effect in any o f  the assays (not shown). Adhesion o f  met, 
IF6, and 530 to the central cell binding domain was partially inhibited 
by a5  or ocv/33 mAbs and adhesion was completely blocked by a
Table 1: Expression of Fn binding integrins on 
melanocytes and melanoma cell lines.
met IF6 530 BLM MV3
control 5* 4 6 5 3
a3 31 45 29 51 57
a4 4 23 19 36 39
Oi5 41 45 33 57 55
ß l 81 87 66 113 127
av 32 29 18 16 15
av/J3 34 32 23 6 3
♦mean fluorescence
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Fig 1: Metastatic capacity of 
human melanoma cell lines. Cells
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Fig 2: Invasion o f human melano- 
cells. Radiolabeled cells were
were inoculated s.c. into nude mice allowed to invade an amniotic base-
and lungs were inspected for nodules 
after 2-3 months.
ment membrane* A filter was used to 
correct for leakage of radioactive de­
bris.
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Fig 5: Inhibition o f adhesion to 
CS-I. Radiolabeled cells
incubated with HP2/1
were 
anti«a4 or
4B4 anti-/? 1 30 min prior to addition 
to CS-I coated wells.
a combi
Fig 6: Inhibition of adhesion to 
the central cell binding domain. NKI- 
SAM1 anti-ctS, LM6Q9 anti-av/33, or 
both were used as in fig. 5 to inhibit 
adhesion to a Fn 120 kDa fragment.
human amniotic basement membrane (fig. 2).
Met and all 4 melanoma cell lines adhere to Fn [3]. Cell adhesion 
can be promoted by several regions o f the Fn molecule including the 
central cell binding domain, the HepII domain, and the CS-I region 
[reviewed in 4], To determine the regions in Fn involved in 
attachment of the various cell lines, we performed adhesion assays to 
a) a 120 kDa Fn fragment containing the central cell binding domain 
but not HepII or CS-I, b) a peptide containing the RGD recognition 
site from the central cell binding domain, c) a CS-I fragment, and d) 
a peptide containing the LDV recognition site from CS-I. Met and
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Fig 3: Adhesion to the central 
cell binding domain. Radiolabeled 
cells were allowed to adhere for 30 
min at 37 *C to wells coated with a 
120 kDa Fn fragment or with a 
GRGDSP peptide coupled to BSA. 
Adherent cells were lysed and 
radioactivity was measured.
Fig 4: Adhesion to the CS-I 
domain. Radiolabeled cells were 
allowed to adhere to wells coated with 
a CS-I peptide coupled to Ig or with a 
EILDV peptide coupled to BSA. 
Adherent cells were lysed 
radioactivity was measured.
and
melanoma cells adhered to the 120 kDa fragment but only met, IF6, 
and 530 adhered to GRGDSP (fig. 3). Melanoma cells but not met 
adhered to CS-I whereas non of the cell lines adhered to EILDV (fig. 
4). As shown in table 1, in contrast to the melanoma cell lines, met 
did not express a4/Sl. This explains the lack of binding of met to CS-I 
since cx4/91 is the receptor for that region in Fn. In line with the 
finding that all cells adhered to the central cell binding domain, they 
all expressed <*301 and aS fil. In addition, met, IF6, and 530, but not 
BLM and MV3 expressed av/53. These are all receptors for RGD in
□  » vont
combination of these mAbs (fig. 6). In contrast, for total inhibition of 
adhesion of BLM and MV3, a 5  mAbs were sufficient (fig. 6).
Lack of adhesion to GRGDSP 
and EILDV by cells that adhere to 
the central cell binding domain 
through «5/51 and to CS-I through 
#401, may be due to expression of 
j31-integrins in a partially active 
state. Therefore we treated the cells 
with TS2/16 anti-/31 mAbs that 
induce a high affinity state of the
TS2/16 induced
O N Q D 8P
ß l  integrins. 
adhesion o f BLM
Fig 7: Induction o f  adhesion to 
(fig. 7) and GRGDSP and EILDV by TS2/16. 
MVS (not shown) to GRGDSP and BLM cells were incubated with 
EILDV, and this adhesion was fully TS2/16 30 min prior to addition to
blocked by a5 and «4  mAbs the wel,s- 
respectively (not shown). No
induction of binding to EILDV was found for met, IF6, or 530.
In conclusion, met and all melanoma cell lines adhere to Fn, but 
differential expression of a4/Sl, a5/51, and av/33 leads to different 
binding mechanisms. For binding their minimal recognition sequence, 
a4/Sl, a5/Jl, but not av/83 require an activating signal. Such signals 
may come from other sites in the Fn molecule and can be mimicked 
by TS2/16. Requirement o f the reported synergy site for c<5/31 binding 
to RGD [5] is indeed modulated by TS2/16 (not shown).
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